Latest Us Markets News

Amgen delivered 8% third-quarter revenue growth and a 19% increase in GAAP diluted EPS, while newer medicines continued to expand. The result came alongside sharp declines in Prolia and XGEVA sales from biosimilar competition and a busy pipeline of late-stage programmes.

Revvity has lifted its full-year 2026 outlook after reporting stronger third-quarter revenue, organic growth and profitability. The life sciences and diagnostics group is also preparing to sell its China immunodiagnostics business for up to US$200 million.

Keurig Dr Pepper delivered a sharp third-quarter sales and adjusted earnings lift, helped by the newly acquired JDE Peet’s coffee business and a US$99 million tariff refund. The company reaffirmed its 2026 targets while carrying substantial acquisition-related debt and integration work.

The FDA has granted orphan drug designation to Neuren’s NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, giving the programme potential US exclusivity and regulatory fee relief. The company is completing a juvenile animal safety study before targeting an IND submission in the first half of 2027.

Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.

Orthocell has recorded its strongest month of US Remplir sales since launch, with 92 units generating A$279,000 in October. The result points to improving surgeon adoption and hospital access, although one month of sales does not yet establish a durable run rate or profitability.

Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.

Resolution Minerals has extended gold mineralisation across its Horse Heaven project in Idaho, including a 500-metre open-ended zone at Golden Gate North. But the quarter ended with just A$1.64 million in cash and an Appendix 5B estimate of 0.2 quarters of funding, placing the proposed debt facility and future capital sources firmly in focus.

Knosys has moved its Libero library platform into active US commercialisation, identifying near-term sales opportunities while preparing for its first customer engagements. The push comes as ARR slips to A$8.7 million and a timing-affected quarter leaves the company with 2.03 quarters of estimated funding.

Bubs Australia has expanded its US footprint to more than 12,000 stores after securing permanent FDA authorisation, but quarterly revenue fell 9.8% and operating cash outflow increased. The company ended September with A$13.4 million of available liquidity, equivalent to 2.2 quarters at the reported cash-burn rate.

4DMedical reported a record first quarter, with scan volumes up 61% to 119,672 and unaudited operating revenue rising 66% to $2.3 million. New contracts across the US, Germany and Australia broaden the commercial story, while $242.8 million in cash gives the company room to keep investing.

Nova Eye Medical delivered 30% year-on-year sales growth in the September quarter, alongside positive operating cash flow and EBITDA. The company confirmed FY27 guidance, but is still seeking to replace a related-party funding facility carrying 15% interest.